Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 135 Show results per page	View Search Criteria \| Help With Results


1.		Phase II/III Study of CDX-110 in Patients With Glioblastoma Multiforme (GBM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Protocol CDX110-003 NCT00458601


2.		Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				0 to 30				Other				EUDRACT 2005-002618-40 BfArM-4030755, EC-105/05, DKS 2006.01, NCT00749723

Last Modified: 1/23/2007 First Published: 11/24/2002


3.		Phase III Randomized Study of Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Patients With Recurrent Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				MRC-BR12 EU-20114, ISRCTN83176944, NCT00052455

Last Modified: 9/15/2008 First Published: 10/25/2004


4.		Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0320 RTOG-0320, NCT00096265

Last Modified: 4/29/2008 First Published: 9/9/2005


5.		Phase III Randomized Study of Radiotherapy Versus Temozolomide in Patients With Low-Grade Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				EORTC-22033 EORTC-26033, EudraCT-2004-002714-11, CAN-NCIC-CE5, NCT00182819, TROG 06.01, CE5


6.		Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Other				TASMC-05-FB-05235-CTIL NCT00268684

Last Modified: 9/18/2008 First Published: 3/13/2006


7.		Phase III Randomized Study of Adjuvant Radiation Therapy and Conventional Temozolomide Versus Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				NCI				RTOG-0525 RTOG-0525, EORTC-26052, EORTC-22053, NCT00304031

Last Modified: 6/11/2008 First Published: 10/21/2006


8.		Phase III Pilot Study of Induction Chemotherapy Followed by Consolidation Myeloablative Chemotherapy Comprising Thiotepa and Carboplatin With or Without Etoposide and Autologous Hematopoietic Stem Cell Rescue in Pediatric Patients With Previously Untreated Malignant Brain Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 10 at diagnosis				Other				CHLA-HEAD-START-III CHLA-HSIII, CHLA-2004-020, CHLA-04.020, NCT00392886, UMN-MT2004-06


9.		A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 and over				Pharmaceutical / Industry				LX01-315 NCT00395070

Last Modified: 5/20/2008 First Published: 5/23/2007


10.		Phase III Randomized Study of Short-Course Radiotherapy With or Without Temozolomide in Older Patients With Newly Diagnosed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Treatment				Active				65 and over				Other, Pharmaceutical / Industry				CAN-NCIC-CE6 EORTC-26062, EORTC-22061, CE6, SPRI-CAN-NCIC-CE.6, NCT00482677

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute